A personalized mRNA vaccine custom-built to match the genetic mutations of each patient's tumor has significantly reduced the risk of skin cancer returning, according to results from a landmark phase III clinical trial. In the global study of 1,137 high-risk melanoma patients whose tumors had been surgically removed, combining the bespoke vaccine, known as intismeran, with the standard immunotherapy drug pembrolizumab lowered the risk of recurrence or death by 42 percent after two years compared to pembrolizumab alone.
Unlike conventional therapies that target a single mutation shared across many cancers, intismeran is tailored to recognize up to 34 specific genetic mutations unique to an individual's melanoma. The treatment uses mRNA technology to train the patient's immune system to identify and destroy residual cancer cells before they can establish new tumors. Among participants receiving the combination therapy, 82 percent were alive and cancer-free at the two-year mark, compared with 70 percent of those on immunotherapy alone.
Professor Georgina Long, medical director at the Melanoma Institute Australia and lead investigator, described the findings as a foundational shift in oncology, noting that harnessing the immune system with this level of individualization has never before succeeded in a phase III cancer trial. The trial results have been accepted for publication in the New England Journal of Medicine, pending formal peer review.
Experts caution, however, that the breakthrough is not an immediate cure-all. Independent cancer researchers noted that a significant proportion of patients do not respond to the vaccine, and tumor cells can eventually evolve to evade immune detection. Furthermore, drug manufacturers emphasized that it remains too early to determine whether the combination will extend overall long-term survival, meaning regulatory review and standard clinical availability are still likely several years away.